-
Je něco špatně v tomto záznamu ?
Novel CYP24A1 Mutation in a Young Male Patient with Nephrolithiasis: Case Report
J. Jiráčková, R. Hyšpler, S. Alkanderi, L. Pavlíková, V. Palicka, JA. Sayer,
Jazyk angličtina Země Švýcarsko
Typ dokumentu kazuistiky
NLK
Directory of Open Access Journals
od 2013
Free Medical Journals
od 2010
ProQuest Central
od 1994-05-01 do Před 1 rokem
ProQuest Central
od 2017-01-01
Open Access Digital Library
od 2013-01-01
Medline Complete (EBSCOhost)
od 2005-01-01
Health & Medicine (ProQuest)
od 1994-05-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2017-01-01
Karger Open Access
od 2013-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1996
PubMed
31288237
DOI
10.1159/000500922
Knihovny.cz E-zdroje
- MeSH
- CYP24A1 genetika MeSH
- hyperkalcemie MeSH
- hyperkalciurie MeSH
- ledvinové kameny genetika MeSH
- lidé MeSH
- mladý dospělý MeSH
- mutace * MeSH
- sekvenční analýza DNA MeSH
- sourozenci MeSH
- vitamin D krev MeSH
- Check Tag
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- Publikační typ
- kazuistiky MeSH
BACKGROUND/AIMS: The CYP24A1 gene encodes the vitamin D 24-hydroxylase enzyme, which hydroxylates active forms of vitamin D into inactive forms. Biallelic mutations in the CYP24A1 gene can lead to elevated levels of active vitamin D metabolites and, consequently, to hypercalcemia, hypercalciuria, nephrocalcinosis, and nephrolithiasis; however, monoallelic mutations have been associated only with milder phenotypes. In the present manuscript, we report the case of a young male patient who presented hypercalcemia and nephrolithiasis, suppressed parathormone, and elevated 1,25 dihydroxy vitamin D levels. METHODS: Biochemical analyses were performed on Cobas 8000, F. Hoffmann-La Roche AG, Basel, Switzerland. The proband was initially evaluated for occult malignancies by body imaging, serum electrophoresis, and tumor markers, which did not reveal any pathology. DNA samples of the proband and his sibling were then examined using Sanger sequencing. RESULTS: Genetic analysis revealed 2 compound heterozygous CYP24A1 mutations (p.L148P and p.R223*). The novel nonsense CYP24A1 mutation, p.R223*, was also found heterozygously in other family members with a medical history of nephrolithiasis. CONCLUSIONS: The identification of this gene mutation causing hypercalcemia, hypercalciuria, and renal stones allows the specific management of endogenous vitamin D production.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20006168
- 003
- CZ-PrNML
- 005
- 20200518132403.0
- 007
- ta
- 008
- 200511s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1159/000500922 $2 doi
- 035 __
- $a (PubMed)31288237
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Jiráčková, Jana $u Institute for Clinical Biochemistry and Diagnostics, Department of Clinical Osteology, University Hospital Hradec Králové, Hradec Králové, Czechia, jana.jirackova@fnhk.cz. Department of Gerontology and Metabolism, University Hospital Hradec Králové, Hradec Králové, Czechia, jana.jirackova@fnhk.cz. Faculty of Medicine, Charles University, Hradec Králové, Czechia, jana.jirackova@fnhk.cz.
- 245 10
- $a Novel CYP24A1 Mutation in a Young Male Patient with Nephrolithiasis: Case Report / $c J. Jiráčková, R. Hyšpler, S. Alkanderi, L. Pavlíková, V. Palicka, JA. Sayer,
- 520 9_
- $a BACKGROUND/AIMS: The CYP24A1 gene encodes the vitamin D 24-hydroxylase enzyme, which hydroxylates active forms of vitamin D into inactive forms. Biallelic mutations in the CYP24A1 gene can lead to elevated levels of active vitamin D metabolites and, consequently, to hypercalcemia, hypercalciuria, nephrocalcinosis, and nephrolithiasis; however, monoallelic mutations have been associated only with milder phenotypes. In the present manuscript, we report the case of a young male patient who presented hypercalcemia and nephrolithiasis, suppressed parathormone, and elevated 1,25 dihydroxy vitamin D levels. METHODS: Biochemical analyses were performed on Cobas 8000, F. Hoffmann-La Roche AG, Basel, Switzerland. The proband was initially evaluated for occult malignancies by body imaging, serum electrophoresis, and tumor markers, which did not reveal any pathology. DNA samples of the proband and his sibling were then examined using Sanger sequencing. RESULTS: Genetic analysis revealed 2 compound heterozygous CYP24A1 mutations (p.L148P and p.R223*). The novel nonsense CYP24A1 mutation, p.R223*, was also found heterozygously in other family members with a medical history of nephrolithiasis. CONCLUSIONS: The identification of this gene mutation causing hypercalcemia, hypercalciuria, and renal stones allows the specific management of endogenous vitamin D production.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hyperkalcemie $7 D006934
- 650 _2
- $a hyperkalciurie $7 D053565
- 650 _2
- $a ledvinové kameny $x genetika $7 D007669
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a mutace $7 D009154
- 650 _2
- $a sekvenční analýza DNA $7 D017422
- 650 _2
- $a sourozenci $7 D035781
- 650 _2
- $a vitamin D $x krev $7 D014807
- 650 _2
- $a CYP24A1 $x genetika $7 D065668
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a kazuistiky $7 D002363
- 700 1_
- $a Hyšpler, Radomir $u Institute for Clinical Biochemistry and Diagnostics, Department of Clinical Osteology, University Hospital Hradec Králové, Hradec Králové, Czechia. Faculty of Medicine, Charles University, Hradec Králové, Czechia.
- 700 1_
- $a Alkanderi, Sumaya $u Institute of Genetic Medicine, Newcastle University, Newcastle, United Kingdom.
- 700 1_
- $a Pavlíková, Ladislava $u Institute for Clinical Biochemistry and Diagnostics, Department of Clinical Osteology, University Hospital Hradec Králové, Hradec Králové, Czechia. Faculty of Medicine, Charles University, Hradec Králové, Czechia.
- 700 1_
- $a Palicka, Vladimir $u Institute for Clinical Biochemistry and Diagnostics, Department of Clinical Osteology, University Hospital Hradec Králové, Hradec Králové, Czechia. Faculty of Medicine, Charles University, Hradec Králové, Czechia.
- 700 1_
- $a Sayer, John A $u Institute of Genetic Medicine, Newcastle University, Newcastle, United Kingdom. Newcastle upon Tyne NHS Hospitals Foundation Trust, Newcastle, United Kingdom. NIHR Newcastle Biomedical Research Centre, Newcastle, United Kingdom.
- 773 0_
- $w MED00003064 $t Kidney & blood pressure research $x 1423-0143 $g Roč. 44, č. 4 (2019), s. 870-877
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31288237 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200518132403 $b ABA008
- 999 __
- $a ok $b bmc $g 1525026 $s 1096224
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 44 $c 4 $d 870-877 $e 20190709 $i 1423-0143 $m Kidney & blood pressure research $n Kidney Blood Press Res $x MED00003064
- LZP __
- $a Pubmed-20200511